Bullish on Ipca Labs, says Gautam Chhaochharia

Gautam Chhaochharia of UBS India told CNBC-TV18, "We like Ipca Labs in the midcap space. Again the pharma story broadly is similar both on the generic front as well as on local business and the valuations are attractive."

The company's trailing 12-month EPS was at Rs 20.31 per share. (Mar, 2013). The stock's price-to-earnings ratio was 29.94. The latest book value of the company is Rs 126.28 per share. At current value, the price-to-book value of the company was 4.81. The dividend yield of the company was 0.53 percent.  The stock's price-to-earnings (P/E) ratio stands at 29.92 on NSE